Crizotinib
规格
877399-52-5CAS 号
638-814-9EC 号
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amineIUPAC 名称
C21H22Cl2FN5O化学式
450.3 g/mol分子量
Crizotinib; 877399-52-5; PF-02341066; (R)-crizotinib; PF-2341066; Xalkori; PF 2341066; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; PF 02341066; crizotinibum; PF2341066; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 53AH36668S; NSC-756645; CHEBI:64310; DTXSID701009329; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; 2-PYRIDINAMINE, 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]-; 3-((1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY)-5-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE; RefChem:57397; PF02341066; L01XE16; DTXCID601436157; MET Tyrosine Kinase Inhibitor PF-02341066; 638-814-9; Crizotinib (PF-02341066); 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; MFCD12407409; CHEMBL601719; Crizotinib (PF-2341066); C21H22Cl2FN5O; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; Xalkori (TN); Crizotinib [USAN]; Crizotinib [USAN:INN]; UNII-53AH36668S; VGH; 877399-52-5 (free base); Crizotinib (Standard); CRIZOTINIB [MI]; CRIZOTINIB [INN]; CRIZOTINIB [JAN]; CRIZOTINIB [VANDF]; CRIZOTINIB [MART.]; CRIZOTINIB [WHO-DD]; SCHEMBL93829; PF-2341066,Crizotinib; Crizotinib (JAN/USAN/INN); Crizotinib - Bio-X trade mark; GTPL4903; orb1223767; orb1307848; orb3141184; CRIZOTINIB [ORANGE BOOK]; Crizotinib, >=98% (HPLC); SCHEMBL29351506; SCHEMBL29622387; EX-A096; Crizotinib (PF-2341066)?; KTEIFNKAUNYNJU-GFCCVEGCSA-N; GLXC-04599; MSK10718; PF 2341066;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; BDBM50306682; EBC-12789; HY-50878R; NSC749005; NSC749769; NSC800080; AKOS015901233; AKOS015995207; CCG-264803; DB08865; FD20585; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; SDCCGSBI-0647655.P002; NCGC00250400-01; NCGC00250400-02; NCGC00250400-03; NCGC00250400-09; NCGC00250400-12; BC164334; BP-43636; HY-50878; C6935; NS00072165; SW202555-3; D09731; F793129; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; BRD-K78431006-001-10-2; BRD-K78431006-001-11-0; 877399-52-5, 877399-53-6 (acetate); Z2065417924; 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; (R)-3-[1-(2,6-Dichloro-3-fluorop henyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine; 3-[(1R)-1-(2,6-dichloro-3-fluoro-phenyl)ethoxy]-5-[1-(4-piperidyl)pyrazol-4-yl]pyridin-2-amine; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyra zol-4-yl]-2-pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine同义词
含有Crizotinib的产品
잴코리캡슐250밀리그램(크리조티닙)잴코리캡슐200밀리그램(크리조티닙)ザーコリカプセル250mgザーコリカプセル200mgXALKORI 50 MG GRANULADO EN CAPSULAS PARA ABRIRXALKORI 20 MG GRANULADO EN CAPSULAS PARA ABRIRXALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIRXALKORI 250 MG CAPSULAS DURASXALKORI 200 MG CAPSULAS DURASXALKORI 250 mg, géluleXALKORI 200 mg, géluleCrizotinib - Aspen Bio
第 1/3 页
销售Crizotinib的公司
ML
MSN LaboratoriesIndiaHD
Hangzhou Dingyan Chem Co., LtdChinaSI
Sinoway Industrial Co.Ltd.ChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaZP
Zison Pharmaceutical (Shandong) Co., LtdChinaHT
Hefei TianRui Pharmaceutical Chemical Co., LtdChina第 1/2 页